The methylation status of GSTP1, APC, and RASSF1 genes in human prostate cancer samples: Comparative analysis of diagnostic informativeness of MS-HRM and hybridization on the Illumina Infinium HumanMethylation450 BeadChip


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

There is a clear need in molecular markers of prostate cancer (PC) that would specify stratification of patients into risk categories and serve as additional parameters to clinical prognostic factors. Altered DNA methylation status is one of molecular processes that occur during PC development. The gene methylation status may be evaluated in laboratory diagnostics by a PCR approach known as means of methylation-sensitive high resolution melting (MS-HRM) curve analysis. This method is particularly promising due to minimal amounts of DNA required for analysis (10 ng). To date, numerous data based on the use of Infinium HumanMethylation450 BeadChip (HM450) technology have been accumulated on DNA methylation in PC samples. However, it remains unclear whether the MS-HRM results are consistent with chip hybridization data. The aim of this study was to perform the comparative analysis of the diagnostic informativeness of MS-HRM and HM450 chip hybridization methods in determination of the methylation status of three genes GSTP1, APC, and RASSF1 in samples obtained from PC patients. The study has shown that using the MS-HRM method it is possible to discriminate PC tumor samples from samples of histologically unaltered prostate tissue by analyzing the methylation status of each gene. Analysis of chip hybridization data confirmed the results obtained by MS-HRM. Differences between tumor tissue and histologically intact tissue obtained from each PC patient in the methylation levels of GSTP1, APC, and RASSF1, determined by MS-HRM or chip hybridization were consistent with each other. Thus, the assessment of the methylation level of gene GSTP1, APC, and RASSF1 using MS-HRM can become the basis for the development of a laboratory test, the specifying diagnosis of prostate cancer.

作者简介

L. Skorodumova

Federal Research and Clinical Center of Physical-Chemical Medicine

编辑信件的主要联系方式.
Email: l.skorodumova@rcpcm.org
俄罗斯联邦, ul. Malaya Pirogovskaya 1a, Moscow, 119435

K. Babalyan

Moscow Institute of Physics and Technology (State University)

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, Dolgoprudniy, Moscow region

R. Sultanov

Moscow Institute of Physics and Technology (State University)

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, Dolgoprudniy, Moscow region

A. Vasiliev

Evdokimov Moscow State Medical Stomatological University (MSMSU)

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, Moscow

A. Govorov

Evdokimov Moscow State Medical Stomatological University (MSMSU)

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, Moscow

D. Pushkar

Evdokimov Moscow State Medical Stomatological University (MSMSU)

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, Moscow

E. Prilepskaya

Evdokimov Moscow State Medical Stomatological University (MSMSU)

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, Moscow

S. Danilenko

Federal Research and Clinical Center of Physical-Chemical Medicine

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, ul. Malaya Pirogovskaya 1a, Moscow, 119435

E. Generozov

Federal Research and Clinical Center of Physical-Chemical Medicine

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, ul. Malaya Pirogovskaya 1a, Moscow, 119435

A. Larin

Federal Research and Clinical Center of Physical-Chemical Medicine

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, ul. Malaya Pirogovskaya 1a, Moscow, 119435

E. Kostryukova

Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow Institute of Physics and Technology (State University)

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, ul. Malaya Pirogovskaya 1a, Moscow, 119435; Dolgoprudniy, Moscow region

E. Sharova

Federal Research and Clinical Center of Physical-Chemical Medicine

Email: l.skorodumova@rcpcm.org
俄罗斯联邦, ul. Malaya Pirogovskaya 1a, Moscow, 119435

补充文件

附件文件
动作
1. JATS XML

版权所有 © Pleiades Publishing, Ltd., 2017